Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 53
- 试验地点
- 4
- 主要终点
- IL1RAP protein expression on the surface of cells detected by flow cytometry
研究概览
简要总结
The tyrosine kinase inhibitor therapy (iTKs) is the first-line treatment of chronic myelogenous leukemia (CML).
Its effectiveness in controlling the progression of the disease is such that it is possible today to consider stopping treatment in patients with deep molecular response (> RM4.0).
Only in about 50% of cases, patients relapse. It has been shown in these patients that hematopoietic stem cells (HSCs) are persistant, quiescent and insensitive to iTKs. These cells are probably at the origin of relapse. It is therefore necessary to develop complementary therapies to cure the disease and consider discontinuation iTKs The development of anti-tumor immunotherapy approach using genetically modified T cells to express a chimeric antigen receptor (CAR) and specifically targeting CML CSH + could address this issue. The membrane expression of the IL-1-RAP protein could be an interesting target.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients for whom there is a strong suspicion of CML diagnosed as part of routine activity.
- •written informed consent
排除标准
- •patient with atypical CML
- •patient with a non SMP CML
- •patients previously treated with interferon
- •patient enrolled in another study therapy or within the exclusion period thereof
- •pregnant or breast-feeding women
- •patient under guardianship, curator or under the protection of justice.
结局指标
主要结局
IL1RAP protein expression on the surface of cells detected by flow cytometry
时间窗: up to 2 years after inclusion
次要结局
未报告次要终点